Literature DB >> 11711684

Antithrombotic therapy for prevention and treatment of ischemic stroke.

G W Albers1.   

Abstract

Atherosclerosis involving the cervical vessels, intracranial vessels, or the aorta is the most common cause of ischemic stroke. Occlusive lesions of small penetrating brain arteries cause small "lacunar" strokes, which account for about 20% of ischemic strokes. Emboli from a variety of cardiac sources, particularly atrial fibrillation, account for about 25%. Efforts to prevent and treat ischemic stroke are complicated by the variety of etiologies underlying it and the selection of antithrombotic or thrombolytic therapy appropriate to the particular etiology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711684     DOI: 10.1023/a:1012709309064

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

Review 1.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  G W Albers; P Amarenco; J D Easton; R L Sacco; P Teal
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

2.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

3.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

4.  Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Authors:  G W Albers; V E Bates; W M Clark; R Bell; P Verro; S A Hamilton
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

5.  Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.

Authors: 
Journal:  JAMA       Date:  1998 Apr 22-29       Impact factor: 56.272

6.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1997-05-31       Impact factor: 79.321

7.  Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.

Authors:  A Algra; J van Gijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

8.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.